Sign up
Pharma Capital

Faron Pharmaceuticals hires chief commercial officer ahead of drug launch

Dr Juhana Heinonen will join the business in January from AstraZeneca
man on a ventilator
The company's flagship drug treats a condition called acute respiratory distress

Faron Pharmaceuticals Oy (LON:FARN), one of a small handful of London-listed drug developers with a product in Phase III clinical trials, said it has appointed a chief commercial officer.

Dr Juhana Heinonen will join the business in January from AstraZeneca PLC (LON:AZN) where he was global marketing director for Fasenra, the company’s asthma treatment.

READ: Faron Pharmaceuticals' £10mln fundraiser will accelerate progress

At Roche, where he worked for seven years to 2015, he oversaw the launch and growth of RoACTEMRA, which eventually became a blockbuster drug for rheumatoid arthritis.

Phase III trial

At Faron, Heinonen will be responsible for the launch and roll out of Traumakine, which is being developed as a life-saving intervention for people with acute respiratory distress. Currently Traumakine is in the late stage of Phase III trials.

Chief executive, Dr Markku Jalkanen, said of the company’s new hire: “He has a wealth of expertise in the commercialisation and marketing of blockbuster drugs, and will be a key addition to the Faron team as we continue our preparations to enter commercialisation.

READ: Faron Pharmaceuticals' lead drug gets significant vote of confidence from UK regulator

“We look forward to benefitting from his experience and valuable insights as our wholly-owned lead product, Traumakine, approaches the completion of its pivotal phase III INTEREST trial."

Ian_55ae0ddd437b7.jpg
Why Invest In Faron Pharmaceuticals Ltd? Read More Here

Register here to be notified of future FARN Company articles
View full FARN profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.